Different criteria for accelerated phase CML
| MD Anderson Cancer Center6 . | Sokal et al19 . | International Bone Marrow Transplant Registry (used in present study)18 . |
|---|---|---|
| PB blasts ≥ 15% | PB or BM blasts ≥ 5% | PB or BM blasts ≥ 10% |
| PB blasts + promyelocytes ≥ 30% | — | PB or BM blasts + promyelocytes ≥ 20% |
| PB basophils ≥ 20% | PB basophils ≥ 20% | PB basophils + eosinophils ≥ 20% |
| Platelet count ≤ 100 × 109/L unrelated to therapy | Thrombopenia unrelated to therapy | Thrombopenia unresponsive to BU or HU therapy |
| Cytogenetic karyotypic evolution | Cytogenetic karyotypic evolution | Cytogenetic karyotypic evolution |
| — | Platelet ≥ 1000 × 109/L despite adequate therapy | Persistent thrombocytosis |
| — | Marrow collagen fibrosis | Myelofibrosis |
| — | Anemia unrelated to therapy | Anemia unresponsive to BU or HU therapy |
| — | Progressive splenomegaly | Progressive splenomegaly |
| — | Leukocyte doubling time < 5 d | Rapid doubling time of leukocytes < 5 d |
| — | Frequent Pelger-Huet-like neutrophils; nucleated erythrocytes; megakaryocyte nuclear fragments | Leukocyte count difficult to control with BU or HU therapy |
| — | Fever not otherwise explained | Development of chloromas |
| MD Anderson Cancer Center6 . | Sokal et al19 . | International Bone Marrow Transplant Registry (used in present study)18 . |
|---|---|---|
| PB blasts ≥ 15% | PB or BM blasts ≥ 5% | PB or BM blasts ≥ 10% |
| PB blasts + promyelocytes ≥ 30% | — | PB or BM blasts + promyelocytes ≥ 20% |
| PB basophils ≥ 20% | PB basophils ≥ 20% | PB basophils + eosinophils ≥ 20% |
| Platelet count ≤ 100 × 109/L unrelated to therapy | Thrombopenia unrelated to therapy | Thrombopenia unresponsive to BU or HU therapy |
| Cytogenetic karyotypic evolution | Cytogenetic karyotypic evolution | Cytogenetic karyotypic evolution |
| — | Platelet ≥ 1000 × 109/L despite adequate therapy | Persistent thrombocytosis |
| — | Marrow collagen fibrosis | Myelofibrosis |
| — | Anemia unrelated to therapy | Anemia unresponsive to BU or HU therapy |
| — | Progressive splenomegaly | Progressive splenomegaly |
| — | Leukocyte doubling time < 5 d | Rapid doubling time of leukocytes < 5 d |
| — | Frequent Pelger-Huet-like neutrophils; nucleated erythrocytes; megakaryocyte nuclear fragments | Leukocyte count difficult to control with BU or HU therapy |
| — | Fever not otherwise explained | Development of chloromas |
PB indicates peripheral blood; BM, bone marrow; BU, busulfan; and HU, hydroxyurea.